| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8551145 | Regulatory Toxicology and Pharmacology | 2018 | 8 Pages |
Abstract
PEGylated recombinant human endostatin (M2ES) exhibited prolonged serum half-life and enhanced antitumor activity when compared with endostatin. A pre-clinical study was performed to evaluate the safety of M2ES in rats. After intravenous (IV) infusions of M2ES at a dose level of 3, 15 and 75â¯mg/kg in Sprague Dawley (SD) rats, M2ES was well tolerated in animals, with no observable changes in clinical observation, body weight, food consumption, urine analysis, hematology and serum biochemical analysis. The increase of kidney weights, and slight to severe vacuolation and necrosis of proximal tubule epithelial cells in kidney were observed in 15 and 75â¯mg/kg M2ES groups, but this adverse-effect was reversible. In summary, the major toxicity target organ of M2ES might be kidney, and the no observed adverse effect level (NOAEL) of M2ES in rats was 3â¯mg/kg in this study. These pre-clinical safety data contribute to the initiation of the ongoing clinical study.
Keywords
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Xingchao Geng, Lifang Guo, Li Liu, Chao Wang, Qian Peng, Weihong Qi, Li Sun, Xiaomeng Liu, Yufa Miao, Zhi Lin, Yan Fu, Yongzhang Luo, Bo Li,